Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Inclusion Criteria: - Men and women with type 2 diabetes mellitus - Age above or equal to 50 years at screening and clinical evidence of cardiovascular disease or age above or equalto 60 years at screening and subclinical evidence of cardiovascular disease - Anti-diabeticdrug naïve, or treated with one or two oral antidiabetic drug (OADs), or treated with humanNeutral Protamin Hagedorn (NPH) insulin or long-acting insulin analogue or pre-mixedinsulin, both types of insulin either alone or in combination with one or two OADs - HbA1c

above or equal to 7.0% at screening Exclusion Criteria: - Type 1 diabetes mellitus - Use ofglucagon-like peptide-1 (GLP-1) receptor agonist (exenatide, liraglutide, or other) orpramlintide within 90 days prior to screening - Use of any dipeptidyl peptidase 4 (DPP-IV)inhibitor within 30 days prior to screening - Treatment with insulin other than basal andpre-mixed insulin within 90 days prior to screening - except for short-term use inconnection with intercurrent illness - Acute decompensation of glycaemic control requiringimmediate intensification of treatment to prevent acute complications of diabetes (egdiabetes ketoacidosis) within 90 days prior to screening - History of chronic pancreatitisor idiopathic acute pancreatitis - Acute coronary or cerebro-vascular event within 90 daysprior to randomisation - Currently planned coronary, carotid or peripheral arteryrevascularisation - Chronic heart failure New York Heart Association (NYHA) class IV -Personal or family history of multiple endocrine neoplasia type 2 (MEN2) or familialmedullary thyroid carcinoma - Personal history of non-familial medullary thyroid carcinoma

• Screening calcitonin above or equal to 50 ng/L